Current Report Filing (8-k)
October 04 2022 - 06:16AM
Edgar (US Regulatory)
0000887247 false 0000887247 2022-10-01
2022-10-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of report (Date of earliest event reported):
October 1, 2022
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
0-26372 |
|
82-0429727 |
| (State or other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
11682 El Camino Real,
Suite 300
San Diego,
CA
|
|
92130 |
| (Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code:
(858)
997-2400
(Former name or Former Address, if Changed Since Last Report.)
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange
Act:
|
Title of each
class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
|
Common Stock |
|
ADMP |
|
NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
| |
Emerging growth company
☐ |
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
| |
Item 5.02. |
Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
On October 1, 2022, Ronald B.
Moss, M.D., the Chief Medical Officer of Adamis Pharmaceuticals
Corporation (the “Company”), notified the Company that he was
resigning as an officer and employee of the Company effective
October 14, 2022.
(d) Exhibits
| Exhibit
No. |
|
Description |
| |
|
|
| 104 |
|
Cover Page Interactive Data File
(embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
ADAMIS
PHARMACEUTICALS CORPORATION |
| |
|
|
| |
|
|
| |
|
|
| Dated: October 3,
2022 |
By: |
/s/ David C. Benedicto |
| |
Name: |
David C. Benedicto |
| |
Title: |
Chief Financial Officer |
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Jan 2023 to Feb 2023
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Feb 2022 to Feb 2023
